WHO ICTRP trial
A Study of Ruxolitinib versus a Best Available Therapy in Patients With Steroid…
CTRI/2017/09/009931 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2017/09/009931 |
|---|---|
| Public title | A Study of Ruxolitinib versus a Best Available Therapy in Patients With Steroid resistant Chronic Graft versus Host Disease After Bone Marrow Transplantation |
| Scientific title | A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation |
| Primary sponsor | Novartis Healthcare Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Denmark;Egypt;Finland;France;Germany;Greece;Hong… |
| Conditions | Health Condition 1: D619- Aplastic anemia, unspecified Health Condition 2: null- Steroid-refractory chronic graft-versus-host disease |
| Interventions | Intervention1: Ruxolitinib: Ruxolitinib twice daily at the protocol defined starting dose Control Intervention1: Best Available Therapy: Extracorporeal photopheresis (ECP); Low-dose methotrexate (MTX); Mycophenolate mofetil (MMF)… |
| Registration date | Sep 27, 2017 |
| Target size | 324 |
| Secondary IDs | CINC424D2301-Protocol version 00 dated 14-Mar-2017;NCT03112603 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: